Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
09 avr. 2024 12h00 HE
|
Imugene Limited
Imugene announced poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the AACR Conference.
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
26 oct. 2023 09h00 HE
|
Mustang Bio, Inc.
MB‐101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus) are separately well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials; preclinical data...
Global Oncolytic Virus Therapies Market Size to Reach USD 1,546.51 Million in 2032 | Emergen Research
23 oct. 2023 09h00 HE
|
Emergen Research
Vancouver, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The global oncolytic virus therapies market size is expected to reach USD 1,546.51 Million at a steady CAGR of 26.2% in 2032, according to latest...
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
07 sept. 2023 16h01 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
10 juil. 2023 07h00 HE
|
Genelux Corporation
Phase 1 trial conducted at Memorial Sloan Kettering Cancer Center, New York, investigated the safety, feasibility and immune activating effects of Olvi-Vec by intrapleural administration. Documented...
Genelux Corporation Announces $18 Million Private Placement
12 juin 2023 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement for 900,000 shares...
Genelux Corporation Announces $33 Million Private Placement
15 mai 2023 07h00 HE
|
Genelux Corporation
WESTLAKE VILLAGE, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced a private placement of 1,665,247 shares...
TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination with Checkpoint Inhibitor
15 mai 2023 02h00 HE
|
TILT Biotherapeutics Oy
HELSINKI, Finland, May 15, 2023 (GLOBE NEWSWIRE) -- TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the first patient has been...
Global Oncolytic Virus Therapy Clinical Pipeline Insight 2028
20 mars 2023 03h21 HE
|
KuicK Research
Delhi, March 20, 2023 (GLOBE NEWSWIRE) -- Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028 Report Overview: Global Oncolytic Virus Immunotherapy Therapy Market...
Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors
15 nov. 2022 16h00 HE
|
Virogin Biotech
VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Virogin Biotech, a clinical-stage biotech company, today announced that the first patient has been dosed in its Phase 1 clinical study...